Join 7000+ optometrists who want to think clearly, lead wisely, and grow profitably. No hype, no fluff. Just what works.
Share
Optometry Simplified Newsletter: Is It really dry eye?, MiSight long-term results, Zoster eye study, allergy drop rankings
Published 2 months ago • 3 min read
Welcome to Optometry Simplified.
In this biweekly newsletter, I've curated the best resources to help you grow personally and professionally.
My mission is to find what's best for my patients and my practice.
Here's what I've found...
Want to listen to an overview of the articles rather than read? Click here
My Favorite Links
When Glaucoma Meets Retina An excellent Review of Optometry article exploring how posterior segment diseases like glaucoma and retinal disorders overlap—and why that convergence is the very heart of primary eye care. Read it here
The Greatest Specialty Contact Lens Story Ever Told If you’ve been looking to build or deepen your specialty lens offerings, this is the overview you’ve been waiting for. It breaks down lens types, indications, and practical tips in one easy-to-digest piece. Read it here
Student Loans Still Looming? If you or your associates are still carrying student debt, this is hands-down the best source I know for staying ahead of upcoming changes and building a smart, personalized payoff plan. Read it here
Journal Articles I'm Applying to Practice
ZEDS: The Zoster Eye Disease Study New evidence from JAMA Ophthalmology supports long-term suppressive antivirals for preventing recurrent herpetic eye disease. Important implications for your chronic viral keratitis patients. Read it here
MiSight Retention After Discontinuation New data show that the axial length gains from MiSight lenses are retained one year after discontinuing therapy—strengthening their role in early myopia management. Read it here
Myopia and Retinal Detachment Risk This ARVO presentation shows significantly higher rates of RD in myopic eyes compared to non-myopic controls. A reminder that preventing axial elongation is more than just about glasses—it’s about preserving the retina. Read it here
Topical Allergy Treatment Rankings This head-to-head meta-analysis ranks the efficacy of ocular allergy drops. If you’re not sure which antihistamine/mast cell stabilizer combo to reach for first, this is your new cheat sheet. Read it here
Deep Dive
One of the biggest shifts in my approach to dry eye disease didn’t come from adding a new drug or device—it came from a mindset change.
Dry Eye Comorbidities, Contributors, and Masqueraders
Early on, I treated dry eye like a standalone disease. If the patient had symptoms, some staining, and reduced tear break-up time, I’d check the boxes and initiate treatment.
But over time, I started noticing a pattern: the patients who got better were rarely the ones where I just treated “dry eye.” They were the ones where I dug deeper and uncovered the true contributors.
Here’s the reality: Dry eye is often just the surface-level expression of something deeper. And unless we get clear on what’s really going on, we risk missing the mark.
Sometimes it’s a masquerader, like epithelial basement membrane dystrophy or recurrent corneal erosions. Sometimes it’s a contributor, like Demodex blepharitis, allergic conjunctivitis, or conjunctivochalasis.
And often, it's a comorbidity stew. In my experience, the degree to which I successfully identify and treat these layered factors is directly correlated with how much relief my patients actually feel.
So I started applying a protocolized approach, beginning with a mindset of curiosity. I ask myself: Is this really dry eye? Or something else mimicking or magnifying it? Then I follow a clinical roadmap that doesn’t just check for DED, but actively rules out the masqueraders and captures the contributors.
That’s where real progress happens. Not just in metrics, but in the look on a patient’s face when they finally say, “Doc, I think this is actually getting better.”
If you’re looking to build a better protocol—and a better approach to comprehensive care—this is exactly what we help ODs do.
Protocols that are evidence-based Systems that are staff-ready Confidence in clinical decision-making
Let’s get one thing out of the way—I’m allergic to overhyped sales language. So I won’t call this a “game-changer” or a “unicorn” (cringe). But the new PPP Pro Membership is hands-down our most complete offer to date.
It combines everything from:
Practice Culture Systems (PCS)
CodeSafePlus (for billing/coding peace of mind)
Eyecode Clinical Protocols & Education
All in one place. One login. One unified strategy for medical growth, compliant systems, and a healthy practice culture. 🔗 Check it out here
Welcome to Optometry Simplified. In this biweekly newsletter, I've curated the best resources to help you grow personally and professionally. My mission is to find what's best for my patients and my practice. Here's what I've found... Links I Liked Should you bill the vision plan or the medical insurance? Chris Wroten, OD gives some practical advice on this common dilemma. Optometry Times How much hydroxychloroquine should our patients be taking? Randall Thomas, OD helps us find the sweet...
Welcome to Optometry Simplified. In this biweekly newsletter, I've curated the best resources to help you grow personally and professionally. My mission is to find what's best for my patients and my practice. Here's what I've found... Links I Liked They've Fit Over 5000 Patients With Scleral Lenses. Learn From Them. Scleral lens fitting isn't something I do every day, so refreshing my knowledge from those who do it all day, every day is extremely helpful. Here are some great clinical pearls...
Welcome to Optometry Simplified. In this biweekly newsletter, I've curated the best resources to help you grow personally and professionally. My mission is to find what's best for my patients and my practice. Here's what I've found... My Favorite Links How Do You Manage These Macular Disorders in Primary Eye Care? In primary eye care, one of the top dozen or so chronic conditions to manage are vitreomacular interface disorders, i.e., epiretinal membranes (ERMs), vitreomacular traction (VMT),...